Identification of the primary gene defect at the cytochrome P450 CYP2D locus
- PMID: 1978251
- DOI: 10.1038/347773a0
Identification of the primary gene defect at the cytochrome P450 CYP2D locus
Abstract
The mammalian cytochrome P450-dependent monooxygenase system is involved in the metabolism of drugs and chemical carcinogens. The role of these enzymes in toxicological response is exemplified by an autosomal recessive polymorphism at the cytochrome P450 CYP2D6 debrisoquine hydroxylase locus which results in the severely compromised metabolism of at least 25 drugs, and which in some cases can lead to life-threatening side-effects. In addition, this polymorphism, which affects 8-10% of the caucasian population, has been associated with altered susceptibility to lung and bladder cancer. Here we report the identification of the primary mutation responsible for this metabolic defect and the development of a simple DNA-based genetic assay to allow both the identification of most individuals at risk of drug side-effects and clarification of the conflicting reports on the association of this polymorphism with cancer susceptibility.
Similar articles
-
Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.IARC Sci Publ. 1991;(115):281-7. IARC Sci Publ. 1991. PMID: 1820342
-
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.Pharmacogenetics. 1993 Jun;3(3):123-30. Pharmacogenetics. 1993. PMID: 8101460
-
Dinucleotide repeat polymorphism at the human debrisoquine 4-hydroxylase (CYP2D) locus.Nucleic Acids Res. 1991 Apr 25;19(8):1961. Nucleic Acids Res. 1991. PMID: 2030982 Free PMC article. No abstract available.
-
Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.Cancer Cells. 1991 Mar;3(3):93-6. Cancer Cells. 1991. PMID: 2054261 Review. No abstract available.
-
[Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].Med Lav. 1992 Nov-Dec;83(6):557-75. Med Lav. 1992. PMID: 1296137 Review. Italian.
Cited by
-
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.AAPS PharmSci. 2000;2(4):E33. doi: 10.1208/ps020433. AAPS PharmSci. 2000. PMID: 11741249 Free PMC article. Clinical Trial.
-
Pharmacogenetics: detecting sensitive populations.Environ Health Perspect. 1994 Dec;102 Suppl 11(Suppl 11):81-7. doi: 10.1289/ehp.94102s1181. Environ Health Perspect. 1994. PMID: 7737047 Free PMC article. Review.
-
Genes and cancer.Arch Dis Child. 1999 Jan;80(1):1-3. doi: 10.1136/adc.80.1.1. Arch Dis Child. 1999. PMID: 10325750 Free PMC article. Review. No abstract available.
-
Pharmacogenetics and gender association with psychotic episodes on nortriptyline lower doses: patient cases.ISRN Pharm. 2011;2011:805983. doi: 10.5402/2011/805983. Epub 2011 Jul 20. ISRN Pharm. 2011. PMID: 22389859 Free PMC article.
-
CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.Pharmgenomics Pers Med. 2018 Oct 24;11:179-191. doi: 10.2147/PGPM.S181334. eCollection 2018. Pharmgenomics Pers Med. 2018. PMID: 30425549 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases